24744-59-0

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
Ethyl (3,5-dibromo-4-hydroxyphenyl)acetate is used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Its unique structure allows for the development of new compounds with therapeutic and pesticidal properties.
Used in Antimicrobial Applications:
Ethyl (3,5-dibromo-4-hydroxyphenyl)acetate has been studied for its potential antimicrobial properties. It can be used as an antimicrobial agent to combat various microorganisms, contributing to the development of new antimicrobial drugs or treatments.
Used in Antioxidant Applications:
ethyl (3,5-dibromo-4-hydroxyphenyl)acetate has also been studied for its potential antioxidant properties. Ethyl (3,5-dibromo-4-hydroxyphenyl)acetate can be used as an antioxidant in various industries, such as food, cosmetics, and pharmaceuticals, to prevent oxidation and extend the shelf life of products.
However, it is important to handle ethyl (3,5-dibromo-4-hydroxyphenyl)acetate with care, as it may have hazardous effects on human health and the environment. Proper safety measures should be taken during its production, use, and disposal to minimize any potential risks.

Upstream product

• 64-17-5 ethanol 
• 24744-58-9 (3,5-dibromo-4-hydroxyphenyl)acetic acid 
• 17138-28-2 (4-hydroxy-phenyl)-acetic acid ethyl ester 
• 156-38-7 4-hydroxyphenylacetate 

Downstream Products

• 117896-43-2 {3,5-Dibromo-4-[4-methoxy-3-(6-methoxy-pyridin-3-ylmethyl)-phenoxy]-phenyl}-acetic acid ethyl ester 
• 24744-57-8 2,6-dibromo-4-hydroxy-4-ethoxycarbonylmethylcyclohexa-2,5-dien-1-one 
• 17194-96-6 2-(3,5-dibromo-4-hydroxyphenyl)acetamide 
• 16420-13-6 N,N-Dimethylthiocarbamoyl chloride 
• 1258517-74-6 2,6-dibromo-1-(p-methoxyphenylacetoxy)benzene-4-acetic acid ethyl ester 
• 15560-90-4 3,5-dibromo-4-(3''-methylbutyloxy)phenylacetic acid ethyl ester 
• 1258517-72-4 2,6-dibromo-1-acetoxybenzene-4-acetic acid ethyl ester 
• 1258517-73-5 2,6-dibromo-1-benzoyloxybenzene-4-acetic acid ethyl ester 
• 1258517-77-9 2,6-dibromo-1-(benzyloxy)benzene-4-acetic acid ethyl ester 
• 1258517-75-7 2,6-dibromo-1-(isonicotinoyloxy)benzene-4-acetic acid ethyl ester 
• 1258517-78-0 2,6-dibromo-1-(p-methoxyphenylpropyloxy)benzene-4-acetic acid ethyl ester 
• 1258517-76-8 2,6-dibromo-1-(trans,trans-farnesyloxy)benzene-4-acetic acid ethyl ester 
• 153535-66-1 4-acetoxy-2,6-dibromo-4-carbamoylmethylcyclohexa-2,5-dien-1-one 
• 17194-81-9 2,6-dibromo-4-hydroxy-4-carbamoylmethylcyclohexa-2,5-dien-1-one 

Relevant academic research and scientific papers

Halogenation of 4-hydroxy/amino-3-methoxyphenyl acetamide TRPV1 agonists showed enhanced antagonism to capsaicin

As an extension of our analysis of the effect of halogenation on thiourea TRPV1 agonists, we have now modified selected 4-hydroxy(or 4-amino)-3- methoxyphenyl acetamide TRPV1 agonists by 5- or 6-halogenation on the aromatic A-region and evaluated them for potency for TRPV1 binding and regulation and for their pattern of agonism/antagonism (efficacy). Halogenation shifted the functional activity at TRPV1 toward antagonism with a greater extent of antagonism as the size of the halogen increased (I > Br > Cl), as previously observed for the thiourea series. The extent of antagonism was greater for halogenation at the 5-position than at the 6-position, in contrast to SAR for the thiourea series. In this series, compounds 55 and 75 showed the most potent antagonism, with Ki (ant) = 2.77 and 2.19 nM, respectively, on rTRPV1 expressed in Chinese hamster ovary cells. The compounds were thus ca. 40-60-fold more potent than 6′-iodononivamide.

4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents

Compounds of general formula (I) STR1 wherein R 1 is (CH 2) n ((CHNR 7 R 8) m C(O)R 9 ; n=1-3; and m=0 or 1;R 3 and R 5 are independently Cl, Br, I, or CH 3 ;R 7 and R 8 are independently H or (C 1 -C 4)alkyl;R 9 is OH, (C 1 -C 4)alkoxy, or NR 7 R 8 ;R 31 is H, Cl, Br, I, (C 1 -C 4)alkyl, (C 4 -C 6)cycloalkyl, (C 1 -C 4)haloalkyl, (C 4 -C 6)halocycloalkyl, or --CH(R 10)Ar where Ar is selected from 5-hydroxypyrid-2-yl, 6-hydroxypyrid-3-yl, 6-hydroxypyridazin-3-yl, 6-methoxypyridazin-3-yl, 6-hydroxypyridazin-3-yl N-oxide, and 6-methoxypyridazin-3-yl N-oxide and R 10 is H or (C 1 -C 4)alkyl;R 41 is OH or a bioprecursor thereof; and the pharmaceutically acceptable salts thereof; are structural analogs of the thyroid hormones T 3 and T 4 and exhibit selective thyromimetic activity. Pharmaceutical compositions of the novel compounds and their use for the treatment of mammalian cholesteremia are provided.